[HTML][HTML] The 2022 World Health Organization classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours

H Moch, MB Amin, DM Berney, EM Compérat, AJ Gill… - European urology, 2022 - Elsevier
The fifth edition of the World Health Organization (WHO) classification of urogenital tumours
(WHO “Blue Book”), published in 2022, contains significant revisions. This review …

The future of early cancer detection

RC Fitzgerald, AC Antoniou, L Fruk, N Rosenfeld - Nature medicine, 2022 - nature.com
A proactive approach to detecting cancer at an early stage can make treatments more
effective, with fewer side effects and improved long-term survival. However, as detection …

[HTML][HTML] The evolution of lung cancer and impact of subclonal selection in TRACERx

AM Frankell, M Dietzen, M Al Bakir, EL Lim, T Karasaki… - Nature, 2023 - nature.com
Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …

[HTML][HTML] Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale… - Cell, 2022 - cell.com
Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …

The evolution of non-small cell lung cancer metastases in TRACERx

M Al Bakir, A Huebner, C Martínez-Ruiz, K Grigoriadis… - Nature, 2023 - nature.com
Metastatic disease is responsible for the majority of cancer-related deaths. We report the
longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from …

Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

K Litchfield, JL Reading, C Puttick, K Thakkar… - Cell, 2021 - cell.com
Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …

[HTML][HTML] Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

K Bi, MX He, Z Bakouny, A Kanodia, S Napolitano… - Cancer cell, 2021 - cell.com
Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients
with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly …

Clear cell renal cell carcinoma ontogeny and mechanisms of lethality

E Jonasch, CL Walker, WK Rathmell - Nature Reviews Nephrology, 2021 - nature.com
The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …

Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial

DA Palma, R Olson, S Harrow, S Gaede… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The oligometastatic paradigm hypothesizes that patients with a limited number of
metastases may achieve long-term disease control, or even cure, if all sites of disease can …

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

DA Braun, Y Hou, Z Bakouny, M Ficial… - Nature medicine, 2020 - nature.com
PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …